Table 5.

Influence of Other Variables in Biomarkers of Collagen Type I Turnover

	PICP (ng/mL)	PICP/B‐AP	ICTP (ng/mL)	ICTP/TRAP5b	MMP1 (ng/mL)	MMP2 (ng/mL)
Demographic
Sex (female)	−48.9a	−7.5a	−0.11a	−0.02	5.7	−55.6
Age, y	0.077	0.071	−0.153	−0.175	−0.334a	−0.277a
Diagnosis
Age at diagnosis, y	−0.059	0.009	−0.142	−0.100	−0.308a	−0.309a
Plasma α‐gal A (female), nmol/h/mL	−0.318	−0.444a	0.028	0.029	0.071	−0.017
Plasma α‐gal A (male), nmol/h/mL	0.120	0.145	0.012	0.035	−0.121	−0.055
Disease severity
MSSI	0.394a	0.287a	0.194	0.189	−0.392a	−0.222
FIPI	0.258a	0.141	0.158	0.043	−0.374a	−0.211
Plasma lyso‐Gb3 (female), nmol/L	0.402a	0.463a	0.225	0.255	−0.123	0.094
Plasma lyso‐Gb3 (male), nmol/L	0.240	0.095	0.171	0.308	0.037	0.266
NT‐proBNP, ng/mL	0.289	0.489a	−0.163	−0.084	−0.533a	−0.262
eGFR, mL/min/1.73 m2	−0.122	−0.081	−0.060	−0.059	0.289a	0.262a
Treatment
ERT (yes)	13.6	3.8	0.03	−0.01	−1.0	−56.3
Age at ERT initiation, y	−0.187	−0.139	−0.217	−0.218	−0.217	−0.220
Time in ERT, y	0.204	0.110	−0.213	−0.288	−0.014	0.146
ACEI/ARB (yes)	−27.0	−1.8	−0.03	−0.04	−8.2	−173.4
β‐Blockers (yes)	6.3	0.2	−0.03	−0.00	4.7	67.5

Data are shown as mean difference for categorical variables and as ρ for continuous variables. ACEI indicates angiotensin‐converting enzyme inhibitors; α‐gal A, α‐galactosidase A; ARB, angiotensin II receptor blockers; B‐AP, bone‐specific alkaline phosphatase; eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; FIPI, Fabry International Prognostic Index; ICTP, carboxyterminal telopeptide of type I collagen; lyso‐Gb3, globotriaosylsphingosine; MMP, matrix metalloproteinase; MSSI, Mainz Severity Score Index; NT‐proBNP, N‐terminal probrain natriuretic peptide; PICP, carboxyterminal propeptide of procollagen type I; TRAP5b, tartrate‐resistant acid phosphatase type 5b.

^a P<0.05.